-+ 0.00%
-+ 0.00%
-+ 0.00%

NewcelX management attends Breakthrough T1D Clinical & Research Congress

PUBT·09/28/2026 12:06:19
Listen to the news
NewcelX management attends Breakthrough T1D Clinical & Research Congress
  • NewcelX management will attend the Breakthrough T1D Clinical & Research Congress in Philadelphia on Oct. 9-11, 2026.
  • Meetings planned with researchers, clinicians, investors, strategic partners on NCEL-101, ahead of a planned Phase 1/2a trial in Type 1 diabetes.
  • Engagement follows a Type B pre-IND meeting with the FDA that aligned on development strategy for NCEL-101.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NLS Pharmaceutics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609280800PRIMZONEFULLFEED9834660) on September 28, 2026, and is solely responsible for the information contained therein.